Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Neurogen Biomarking LLC
Study ID
NCT07701161
Status
Recruiting

Conditions

  • Alzheimer s Disease
  • Biomarkers
  • MCI Conversion to Dementia
  • pTau217

Eligibility Criteria

Sex
ALL
Age
40 Years - 90 Years
Healthy Volunteers
Accepted

Study Details

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Key Dates

First listed
Jul 14, 2026
Start date
Jan 13, 2025
Status verified
Jul 2026
Primary completion
Mar 20, 2026
Completion
Aug 1, 2026

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: AD subjects
    Amyloid PET/CSF confirmed and clinically diagnosed
  • Arm: Healthy Controls
    No history of cognitive impairment
  • Arm: Non-AD cognitively impaired (amyloid-negative)
    Cognitive impairment not due to AD, confirmed amyloid-negative via PET/CSF

Primary Outcome Measure

Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture blood [ Time Frame: Baseline ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Insigth Hospital and Medical Center ChicagoChicagoIllinois60616
Ansam Eghzawi, MD
+18109410076
Elisabeth Thijssen, PhD
+16282788161
Insight Hospital and Medical Center DearbornDearbornMichigan48126-
Insight Institute of Neurology and NeurosurgeryFlintMichigan48507-
Memorial Healthcare HospitalOwossoMichigan48867-
Wake Forest Baptist Medical CenterWinston-SalemNorth Carolina27157-

Find similar trials in Chicago, IL

Related Studies